오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - fluconazole, quantity: 2 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - fluconazole-baxter intravenous infusion should be used only when fluconazole cannot be administered orally: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). 3. treatment of oropharyngeal and oesophageal candidiasis in patients with aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. 5. vaginal candidiasis, when topical therapy has failed. 6. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - carboplatin -

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 45 g (equivalent: glucose monohydrate, qty 50 g) - injection - excipient ingredients: water for injections - glucose (5%) intravenous infusions are mainly indicated: - whenever non-electrolyte fluid replacement is required. - as a vehicle for drug delivery, provided that the added components are compatible with glucose.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 22.5 g (equivalent: glucose monohydrate, qty 25 g) - injection - excipient ingredients: water for injections - glucose (5%) intravenous infusions are mainly indicated: - whenever non-electrolyte fluid replacement is required. - as a vehicle for drug delivery, provided that the added components are compatible with glucose.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 11.25 g (equivalent: glucose monohydrate, qty 12.5 g) - injection - excipient ingredients: water for injections - glucose (5%) intravenous infusions are mainly indicated: - whenever non-electrolyte fluid replacement is required. - as a vehicle for drug delivery, provided that the added components are compatible with glucose.

싱가포르 - 영어 - HSA (Health Sciences Authority)

baxter healthcare (asia) pte ltd - gastroenterology & urology - baxter's homechoice claria apd cycler is intended for automatic control of dialysis solution exchanges in the treatment of pediatric and adult renal failure patients undergoing peritoneal dialysis.

싱가포르 - 영어 - HSA (Health Sciences Authority)

baxter healthcare (asia) pte ltd - general hospital - baxter irrigation sets are indicated for the delivery of irrigating solutions from the fluid container to the irrigation site during bladder irrigation or endoscopic procedures including cytoscopy, transurethral resection and arthroscopic procedures. the sets are intended for use with baxter irrigating solutions in plastic containers such as uromatic(r) or arthromatic (r) plastic containers.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - ketamine hydrochloride 115.34 mg/ml equivalent to ketamine 100 mg/ml - solution for injection - 100 mg/ml - active: ketamine hydrochloride 115.34 mg/ml equivalent to ketamine 100 mg/ml excipient: nitrogen water for injection - ketamine-baxter is recommended: 1. as the sole anaesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation. ketamine-baxter is best suited for short procedures and it can be used with additional doses, for longer procedures; 2. for the induction of anaesthesia prior to the administration of other general anaesthetic agents; 3. to supplement low-potency agents, such as nitrous oxide.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - bupivacaine hydrochloride, quantity: 5 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 5.28 mg/ml) - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; sodium hydroxide; water for injections - indications ,bupivacaine-baxter is indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: ,surgical anaesthesia ,epidural block for surgery ,field block (minor and major nerve blocks and infiltration). ,analgesia ,continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. ,field block (minor nerve block and infiltration).

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - bupivacaine hydrochloride, quantity: 2.5 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 2.64 mg/ml) - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium chloride; sodium hydroxide - indications ,bupivacaine-baxter is indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: ,surgical anaesthesia ,epidural block for surgery ,field block (minor and major nerve blocks and infiltration). ,analgesia ,continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. ,field block (minor nerve block and infiltration).